A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North central cancer treatment group study N0326
Grace K. Dy, Shauna L. Hillman, Kendrith M. Rowland, Julian R. Molina, Preston D. Steen, Donald B. Wender, Suresh Nair, Sumithra Mandrekar, Steven E. Schild, Alex A. Adjei
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North central cancer treatment group study N0326'. Together they form a unique fingerprint.